Trial · NCT01023620
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
NCT01023620, Not applicable, Completed, University of Texas Southwestern Medical Center; results first posted 2019-10-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone). Trials, record NCT01023620. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01023620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
- NCT number
- NCT01023620
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- HIV Infections
- Interventions
- Pioglitazone, Observation
- First posted
- 2009-12-02
- Last updated
- 2019-10-08
- Results first posted
- 2019-10-08
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg | 16 weeks | No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed |
| Secondary | Fine Needle Aspiration of Fat Pre/Post With Daily Pioglitazone 45 mg | 16 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg | 16 weeks | No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed | ||
| SECONDARY | Fine Needle Aspiration of Fat Pre/Post With Daily Pioglitazone 45 mg | 16 weeks | Investigator left the university mid way through the study and unable to find him. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pioglitazone | 0 | |
| Overall Study | STARTED | Observation/Comparison | 0 | |
| Overall Study | COMPLETED | Pioglitazone | 0 | |
| Overall Study | COMPLETED | Observation/Comparison | 0 | |
| Overall Study | NOT COMPLETED | Pioglitazone | 0 | |
| Overall Study | NOT COMPLETED | Observation/Comparison | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pioglitazone | ||
| Total, all-cause mortality | Observation/Comparison | ||
| Total, other adverse events | Pioglitazone | 0 | 0 |
| Total, other adverse events | Observation/Comparison | 0 | 0 |
| Total, serious adverse events | Pioglitazone | 0 | 0 |
| Total, serious adverse events | Observation/Comparison | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01023620
GET https://conductscience.org/api/trials/v1/NCT01023620/registered